Bank of America (BofA) Securities on Wednesday initiated coverage on Ligand Pharmaceuticals Inc LGND, citing the distinctive ...

Ligand Pharmaceuticals (LGND) stock jumps premarket as BofA starts its coverage with a Buy rating and a $244 target, citing ...

The fair value estimate for Ligand Pharmaceuticals has been nudged higher, moving from US$243.44 to US$244.56 in the latest analyst update. That shift is closely tied to refreshed views on QTORIN and ...

Shares of Ligand Pharmaceuticals dropped into a sell zone Thursday, seemingly down in sympathy with the broader biotech segment.

Bank of America has initiated coverage of Ligand Pharmaceuticals Inc (NASDAQ:LGND) with a Buy rating and a $244 price target, citing the company’s royalty-focused business model and diversified ...

Summers Value Partners, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Summers Value Fund LP returned a net return ...

4 analysts have expressed a variety of opinions on Ligand Pharmaceuticals (NASDAQ:LGND) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a ...

As of Thursday, February 26, Ligand Pharmaceuticals Incorporated’s LGND share price has dipped by 5.99%, which has investors questioning if this is right time to buy.

Delaware-based Ashford Capital Management sold 58,097 shares of Ligand Pharmaceuticals for an estimated $8.9 million in the third quarter. The transaction value equaled about 1% of 13F reportable ...